Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Christiane Copie Bergman, MDPhD, Elodie Bohers, PhD, Peggy Dartigues-Cuillères, MD, Pierre-Julien Viailly, Philippe Ruminy, PhD, Vinciane Marchand, Marie-Helene Delfau-Larue, Corinne Haioun, MDPhD, Cyrielle Robe, Elsa Poullot, MD, Steven Le Gouill, MD PhD, Yannick Le Bris, PharmD, Céline Bossard, MD, Anne Moreau, MD, Vincent Ribrag, MD, Valérie Camara-clayette, PhD, Cyril Quivoron, PhD, Gilles Salles, MDPhD, Sophie Cotteret, MD PhD, Pierre Sujobert, MD PhD, Alexandra Traverse-Glehen, MD PhD, Claire Mauduit, Pascaline Etancelin, Sarah Huet, Liana Veresezan, MD, Krimo Bouabdallah, MD, Marie Parrens, MD, Audrey Gros, PhD, Samuel Amintas, David Sibon, MD PhD, Ludovic Lhermitte, MD PhD, Thomas Steimle, Sophie Kaltenbach, Bettina Fabiani, MD, Camille Laurent, MD PhD, Barbara Burroni, Laurent Martin, MD PhD, Thierry Jo Molina, MDPhD, Lysa LYSARC study group, Fabrice Jardin, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141953

Published: 2020

Journal Articles

A Transcriptomic Continuum of Differentiation Arrest in Acute Leukemia

Jonathan Bond, Aleksandra Krzywon, Ludovic Lhermitte, MD PhD, Christophe Roumier, PharmD, Anne Roggy, Mohamed Belhocine, PhD MSc, BSc, Alexander Kheirallah, Patrick Villarese, PhD, Guillaume Hypolite, Francine Garnache-Ottou, D.Pharm PhD, Herve Dombret, MD PhD, Nicolas Boissel, MD PhD, Claude Preudhomme, PharmD, PhD, Vahid Asnafi, MD PhD, Elisa Laurenti, PhD, Elizabeth Macintyre, PhDMD

Blood (2019) 134 (Supplement_1): 2511.

https://doi.org/10.1182/blood-2019-125902

Published: 2019

Journal Articles

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

Danielle Canioni, MD, Josquin Moraly, MD, Ludovic Lhermitte, MD PhD, Laura Polivka, MD, Mélanie Féroul, Julien Rossignol, MD PhD, Laurent Frenzel, MD PhD, Michel Arock, pharmD, PhD, Patrice Dubreuil, PhD, Leila maouche-Chretien, PhD, Olivier Hermine, MD PhD

Blood (2019) 134 (Supplement_1): 1683.

https://doi.org/10.1182/blood-2019-131256

Published: 2019

Journal Articles

The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL)

Aurélie Cabannes, MD, Aline Schmidt, MD, Eolia Brissot, MD PhD, Marie Balsat, MD, Sébastien Maury, MD PhD, Francoise Isnard, MD PhD, Patrice Chevallier, MD, Victoria Cacheux, Thomas Cluzeau, MD PhD, Carlos Graux, Ludovic Lhermitte, MD PhD, Herve Dombret, MD PhD, Nicolas Boissel, MD PhD, Vahid Asnafi, MD PhD, Philippe Rousselot, MD PhD

Blood (2019) 134 (Supplement_1): 1339.

https://doi.org/10.1182/blood-2019-130818

Published: 2019

Journal Articles

Omalizumab: Efficacy and Safety in Mast Cell Disorders

Richard Lemal, MD, Guillemette Fouquet, Louis Terriou, MD, Mélanie Vaes, MD, Cristina Livideanu, MD, Laurent Frenzel, MD PhD, Stéphane Barete, Danielle Canioni, MD, Ludovic Lhermitte, MD PhD, Jacques-Olivier Bay, MD PhD, Julien Rossignol, MD PhD, Michel Arock, Olivier Lortholary, Olivier Hermine, MD PhD

Blood (2018) 132 (Supplement 1): 4280.

https://doi.org/10.1182/blood-2018-99-114739

Published: 2018

Journal Articles

Longitudinal Evolution and Clinical Impact of Subclonal Mutational Architecture in Adult T Cell Leukemia/Lymphoma

Ambroise Marçais, MD PhD, Ludovic Lhermitte, MD PhD, Maria Artesi, Keith Durkin, Vincent Hahaut, Véronique Avettand Fenoel, Julie Bruneau, MD PhD, Felipe Suarez, MD PhD, Claudine Pique, Anne Van den Broeke, Vahid Asnafi, MD PhD, Olivier Hermine, MD PhD

Blood (2018) 132 (Supplement 1): 2841.

https://doi.org/10.1182/blood-2018-99-115961

Published: 2018

Journal Articles

Successful Salvage Therapy By Idelalisib Followed By Haploidentical Allogenic Transplantation of an Alemtuzumab-Refractory T-Cell Prolymphocytic Leukemia

Julien Lenglet, MD, Amélie Trinquand, MD, Ludovic Lhermitte, MD PhD, Ali Bazarbachi, MD PhD, Laurent Frenzel, MD PhD, Olivier Tournilhac, MD PhD, Olivier Hermine

Blood (2015)

https://doi.org/10.1182/blood.V126.23.5071.5071

Published: 2015

NARROW

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

A Transcriptomic Continuum of Differentiation Arrest in Acute Leukemia

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL)

Omalizumab: Efficacy and Safety in Mast Cell Disorders

Longitudinal Evolution and Clinical Impact of Subclonal Mutational Architecture in Adult T Cell Leukemia/Lymphoma

Successful Salvage Therapy By Idelalisib Followed By Haploidentical Allogenic Transplantation of an Alemtuzumab-Refractory T-Cell Prolymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

A Transcriptomic Continuum of Differentiation Arrest in Acute Leukemia

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL)

Omalizumab: Efficacy and Safety in Mast Cell Disorders

Longitudinal Evolution and Clinical Impact of Subclonal Mutational Architecture in Adult T Cell Leukemia/Lymphoma

Successful Salvage Therapy By Idelalisib Followed By Haploidentical Allogenic Transplantation of an Alemtuzumab-Refractory T-Cell Prolymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only